$599

Lexicon Q2 ’18 Earnings Update

Lexicon hosted its Q2 ’18 earnings call and provided updates on sotagliflozin. Discussion centered on the potential FDA adcom for sotagliflozin in T1DM, DKA consensus guidelines being developed by ATTD, and the benefit of sotagliflozin in reducing hypoglycemia.

This content is for Read Less members only.
Register
Already a member? Log in here